BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37140380)

  • 1. The CD56-CD16+ NK cell subset in chronic infections.
    Cocker ATH; Guethlein LA; Parham P
    Biochem Soc Trans; 2023 Jun; 51(3):1201-1212. PubMed ID: 37140380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Hope for CD56
    Forconi CS; Oduor CI; Oluoch PO; Ong'echa JM; Münz C; Bailey JA; Moormann AM
    Front Cell Infect Microbiol; 2020; 10():162. PubMed ID: 32373555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.
    Vargas-Inchaustegui DA; Demberg T; Robert-Guroff M
    Immunology; 2011 Nov; 134(3):326-40. PubMed ID: 21978002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD56
    Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
    Front Immunol; 2019; 10():14. PubMed ID: 30761123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort.
    Bayigga L; Nabatanzi R; Sekiziyivu PN; Mayanja-Kizza H; Kamya MR; Kambugu A; Olobo J; Kiragga A; Kirimunda S; Joloba M; Nakanjako D
    BMC Immunol; 2014 Jan; 15():2. PubMed ID: 24483185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD16- natural killer cells: enrichment in mucosal and secondary lymphoid tissues and altered function during chronic SIV infection.
    Reeves RK; Gillis J; Wong FE; Yu Y; Connole M; Johnson RP
    Blood; 2010 Jun; 115(22):4439-46. PubMed ID: 20339088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK Cell Subsets Changes in Partial Remission and Early Stages of Pediatric Type 1 Diabetes.
    Gomez-Muñoz L; Perna-Barrull D; Villalba A; Rodriguez-Fernandez S; Ampudia RM; Teniente-Serra A; Vazquez F; Murillo M; Perez J; Corripio R; Bel J; Vives-Pi M
    Front Immunol; 2020; 11():611522. PubMed ID: 33569058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of CCR7 expression on CD56(bright) NK cells is associated with a CD56(dim)CD16⁺ NK cell-like phenotype and correlates with HIV viral load.
    Hong HS; Ahmad F; Eberhard JM; Bhatnagar N; Bollmann BA; Keudel P; Ballmaier M; Zielinska-Skowronek M; Schmidt RE; Meyer-Olson D
    PLoS One; 2012; 7(9):e44820. PubMed ID: 23028633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD56
    Wang H; Zeng Y; Zhang M; Ma H; Xu B; Jiang H; Wang J; Li G
    Hum Immunol; 2019 Oct; 80(10):871-877. PubMed ID: 31326139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terminal Differentiation of CD56(dim)CD16(+) Natural Killer Cells Is Associated with Increase in Natural Killer Cell Frequencies After Antiretroviral Treatment in HIV-1 Infection.
    Ahmad F; Tufa DM; Mishra N; Jacobs R; Schmidt RE
    AIDS Res Hum Retroviruses; 2015 Dec; 31(12):1206-12. PubMed ID: 26352913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56
    Euchner J; Sprissler J; Cathomen T; Fürst D; Schrezenmeier H; Debatin KM; Schwarz K; Felgentreff K
    Front Immunol; 2021; 12():640672. PubMed ID: 34017328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset.
    Harlin H; Hanson M; Johansson CC; Sakurai D; Poschke I; Norell H; Malmberg KJ; Kiessling R
    J Immunol; 2007 Oct; 179(7):4513-9. PubMed ID: 17878347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD56
    Ma M; Yin X; Zhao X; Guo C; Zhu X; Liu T; Yang M; Zhang Z; Fu Y; Liu J; Xu J; Ding H; Han X; Chu Z; Shang H; Jiang Y
    J Leukoc Biol; 2019 Dec; 106(6):1313-1323. PubMed ID: 31483071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferative and cytotoxic capabilities of CD16+CD56- and CD16+/-CD56+ natural killer cells.
    Søndergaard SR; Ullum H; Pedersen BK
    APMIS; 2000 Dec; 108(12):831-7. PubMed ID: 11252817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immune potential of decidua-resident CD16
    Zhang J; Lye SJ
    Hum Immunol; 2021 May; 82(5):332-339. PubMed ID: 33583640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
    Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of the CD16(-)CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer.
    Koo KC; Shim DH; Yang CM; Lee SB; Kim SM; Shin TY; Kim KH; Yoon HG; Rha KH; Lee JM; Hong SJ
    PLoS One; 2013; 8(11):e78049. PubMed ID: 24223759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-dependent CD56+ T cell responses are functionally impaired in long-term HIV-1 infection.
    Fan X; Zhu L; Liang H; Xie Z; Huang X; Wang S; Shen T
    Retrovirology; 2016 Nov; 13(1):76. PubMed ID: 27814766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biology of human natural killer-cell subsets.
    Cooper MA; Fehniger TA; Caligiuri MA
    Trends Immunol; 2001 Nov; 22(11):633-40. PubMed ID: 11698225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of CD56
    Casado JL; Moraga E; Vizcarra P; Velasco H; Martín-Hondarza A; Haemmerle J; Gómez S; Quereda C; Vallejo A
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.